Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning
Abstract Purpose No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with non–human papillomavirus...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-02-01
|
| Series: | Journal of Otolaryngology - Head and Neck Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40463-023-00623-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544027827765248 |
|---|---|
| author | Tsung-Ming Chen Wan-Ming Chen Mingchih Chen Ben-Chang Shia Szu-Yuan Wu |
| author_facet | Tsung-Ming Chen Wan-Ming Chen Mingchih Chen Ben-Chang Shia Szu-Yuan Wu |
| author_sort | Tsung-Ming Chen |
| collection | DOAJ |
| description | Abstract Purpose No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with non–human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Patients and Methods We included patients with stage I–IVA p16-negative OPSCC receiving definitive CCRT and categorized them into two groups according to pre-CCRT 18FDG PET–CT and compared their outcomes: the case group consisted of patients who underwent pre-CCRT 18FDG PET–CT, whereas the comparison group consisted of patients who did not receive pre-CCRT 18FDG PET–CT. Results The final cohort consisted of 3942 patients (1663 and 2279 in the case and comparison groups, respectively). According to multivariable Cox regression analysis, pre-CCRT 18FDG PET–CT was not a significant prognostic factor for overall survival in patients with stages I–II of p16-negative OPSCC receiving standard CCRT. The adjusted hazard ratio (95% confidence interval) of all-cause death for the patients with advanced stages (III–IVA) of p16-negative OPSCC receiving pre-CCRT 18FDG PET–CT was 0.75 (0.87–0.94, P = 0.0236). Conclusions Routine use of pre-CCRT 18FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT 18FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OSCC, but might be not in those with stage I–II p16-negative OPSCC. Condensed abstract No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC). Our study is the first, largest, homogenous modality study on PET–CT including a long-term follow-up cohort to examine the survival outcomes of pre-CCRT 18FDG PET–CT or non-pre-CCRT PET–CT for patients with p16-negative OPSCC receiving standard CCRT stratified by different clinical stages. Routine use of pre-CCRT 18FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT 18FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OPSCC, but might be not in those with stage I–II p16-negative OPSCC. |
| format | Article |
| id | doaj-art-f426c80e0287456da7f5aac7fa11c696 |
| institution | Kabale University |
| issn | 1916-0216 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Otolaryngology - Head and Neck Surgery |
| spelling | doaj-art-f426c80e0287456da7f5aac7fa11c6962025-02-03T11:13:52ZengSAGE PublishingJournal of Otolaryngology - Head and Neck Surgery1916-02162023-02-0152111310.1186/s40463-023-00623-yPre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planningTsung-Ming Chen0Wan-Ming Chen1Mingchih Chen2Ben-Chang Shia3Szu-Yuan Wu4Department of Otolaryngology-Head and Neck Surgery, Shuang Ho Hospital, Taipei Medical UniversityGraduate Institute of Business Administration, College of Management, Fu Jen Catholic UniversityGraduate Institute of Business Administration, College of Management, Fu Jen Catholic UniversityGraduate Institute of Business Administration, College of Management, Fu Jen Catholic UniversityGraduate Institute of Business Administration, College of Management, Fu Jen Catholic UniversityAbstract Purpose No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with non–human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Patients and Methods We included patients with stage I–IVA p16-negative OPSCC receiving definitive CCRT and categorized them into two groups according to pre-CCRT 18FDG PET–CT and compared their outcomes: the case group consisted of patients who underwent pre-CCRT 18FDG PET–CT, whereas the comparison group consisted of patients who did not receive pre-CCRT 18FDG PET–CT. Results The final cohort consisted of 3942 patients (1663 and 2279 in the case and comparison groups, respectively). According to multivariable Cox regression analysis, pre-CCRT 18FDG PET–CT was not a significant prognostic factor for overall survival in patients with stages I–II of p16-negative OPSCC receiving standard CCRT. The adjusted hazard ratio (95% confidence interval) of all-cause death for the patients with advanced stages (III–IVA) of p16-negative OPSCC receiving pre-CCRT 18FDG PET–CT was 0.75 (0.87–0.94, P = 0.0236). Conclusions Routine use of pre-CCRT 18FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT 18FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OSCC, but might be not in those with stage I–II p16-negative OPSCC. Condensed abstract No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET–CT) in patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC). Our study is the first, largest, homogenous modality study on PET–CT including a long-term follow-up cohort to examine the survival outcomes of pre-CCRT 18FDG PET–CT or non-pre-CCRT PET–CT for patients with p16-negative OPSCC receiving standard CCRT stratified by different clinical stages. Routine use of pre-CCRT 18FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT 18FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OPSCC, but might be not in those with stage I–II p16-negative OPSCC.https://doi.org/10.1186/s40463-023-00623-yConcurrent chemoradiotherapy18FDG PET–CTOPSCCSurvivalClinical stages |
| spellingShingle | Tsung-Ming Chen Wan-Ming Chen Mingchih Chen Ben-Chang Shia Szu-Yuan Wu Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning Journal of Otolaryngology - Head and Neck Surgery Concurrent chemoradiotherapy 18FDG PET–CT OPSCC Survival Clinical stages |
| title | Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning |
| title_full | Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning |
| title_fullStr | Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning |
| title_full_unstemmed | Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning |
| title_short | Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning |
| title_sort | pre ccrt 18 fluorodeoxyglucose pet ct improves survival in patients with advanced stages p16 negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning |
| topic | Concurrent chemoradiotherapy 18FDG PET–CT OPSCC Survival Clinical stages |
| url | https://doi.org/10.1186/s40463-023-00623-y |
| work_keys_str_mv | AT tsungmingchen preccrt18fluorodeoxyglucosepetctimprovessurvivalinpatientswithadvancedstagesp16negativeoropharyngealsquamouscellcarcinomaviaaccurateradiationtreatmentplanning AT wanmingchen preccrt18fluorodeoxyglucosepetctimprovessurvivalinpatientswithadvancedstagesp16negativeoropharyngealsquamouscellcarcinomaviaaccurateradiationtreatmentplanning AT mingchihchen preccrt18fluorodeoxyglucosepetctimprovessurvivalinpatientswithadvancedstagesp16negativeoropharyngealsquamouscellcarcinomaviaaccurateradiationtreatmentplanning AT benchangshia preccrt18fluorodeoxyglucosepetctimprovessurvivalinpatientswithadvancedstagesp16negativeoropharyngealsquamouscellcarcinomaviaaccurateradiationtreatmentplanning AT szuyuanwu preccrt18fluorodeoxyglucosepetctimprovessurvivalinpatientswithadvancedstagesp16negativeoropharyngealsquamouscellcarcinomaviaaccurateradiationtreatmentplanning |